ALLMedicine™ Mesothelioma Center

May 14th, 2022 - Inhalation of asbestos fibers can cause malignant mesothelioma, a rapidly progressing and lethal cancer of the mesothelium, the thin layer of tissues surrounding internal organs in the chest and abdomen. Patients with malignant mesothelioma have a...

May 13th, 2022 - Background: LMB-100, and a closely related immunotoxin, SS1P, also targeting mesothelin, given intravenously, have been studied in Phase 1 clinical studies for mesothelioma and pancreatic cancer. LMB-100 given intravenously, results in systemic in...

May 13th, 2022 - PRIMARY OBJECTIVE: I. To detect an improvement in overall survival with the addition of adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) to surgery and chemotherapy compared to surgery and chemotherapy alone. SECONDARY...

May 10th, 2022 - Malignant mesothelioma (MMe) is an aggressive rare cancer of the mesothelium, associated with asbestos exposure. MMe is currently an incurable disease at all stages mainly due to resistance to treatments. It is therefore necessary to elucidate key...

May 10th, 2022 - Current methodologies for the expansion of primary tumor cell lines from rare tumor types are lacking. This protocol describes methods to expand primary tumor cells from surgically resected, malignant pleural mesothelioma (MPM) by providing a comp...

Dec 4th, 2021 - Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.|2021|Popat S,Baas P,Faivre-Finn C,Girard N,Nicholson AG,|

Feb 5th, 2021 - Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in ...

Mar 27th, 2020 - Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.|2020|Kusamura S,Kepenekian V,Villeneuve L,Lurvink RJ,Govaerts K,|diagnosis,pathology,therapy,diagnosis,pathology,therapy,

Jul 29th, 2018 - Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and thoracic surgeons alike. In recent years, several well-designed randomised clinical trials have been published that have changed the landscape of MPE m...

Mar 9th, 2018 - Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary.|2018|Kindler HL,Ismaila N,Hassan R,|diagnosis,therapy,diagnosis,therapy,diagnosis,therapy,

May 13th, 2022 - Background: LMB-100, and a closely related immunotoxin, SS1P, also targeting mesothelin, given intravenously, have been studied in Phase 1 clinical studies for mesothelioma and pancreatic cancer. LMB-100 given intravenously, results in systemic in...

May 13th, 2022 - PRIMARY OBJECTIVE: I. To detect an improvement in overall survival with the addition of adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) to surgery and chemotherapy compared to surgery and chemotherapy alone. SECONDARY...

May 10th, 2022 - For patients with this type of cancer, the standard of care is treatment with chemotherapy. Radiation therapy is typically not used. This is because radiation to the entire lining of the lung has many side effects that are often severe including d...

May 5th, 2022 - The trial combines two (Gemcitabine and Atezolizumab). Gemcitabine, alone or in combination regimens is a standard of care for several solid tumors, such as advanced or metastatic NSCLC. It is also used in an off-label setting for pre-treated MPM ...

May 2nd, 2022 - PRIMARY OBJECTIVES: I. To establish the maximum tolerated dose (MTD) and the recommended phase II dose of cediranib maleate (cediranib) in combination with cisplatin and pemetrexed disodium (pemetrexed). (Phase I) II. To assess the safety and toxi...

May 2nd, 2022 - The addition of SOT101, an interleukin (IL)-2/IL-15 Rβγ superagonist, to Pembrolizumab (Keytruda) generated a clinical benefit and encouraging safety data in patients with advanced solid tumors, according to data presented at the 2022 AACR Annual ...

Apr 22nd, 2022 - Cancer patients treated with immune checkpoint inhibitors (ICIs) had different tradeoffs in neurologic side effects compared with users of other medications, according to a meta-analysis of over three dozen randomized trials. Pooling data from 39 ...

Mar 18th, 2022 - As director of 3 centers at Dana-Farber Cancer Institute, a professor of medicine at Harvard Medical School, and head of The Jänne Lab, you might wonder what master plan Pasi A. Jänne, MD, PhD, drafted in his youth to make him so successful. The ...

Mar 1st, 2022 - LiPax (TSD-001), a precision-targeted, locally-delivered taxane, was found to induce a recurrence-free survival (RFS) rate of 83% in patients with non–muscle invasive bladder cancer (NMIBC) who had undergone transurethral resection of bladder tumo...

Feb 17th, 2022 - A drug that made its mark in breast cancer showed preliminary activity in its first-ever clinical trial in mesothelioma. The cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib (Verzenio) achieved disease control at 12 weeks in 14 of 26 patien...